389 related articles for article (PubMed ID: 7648380)
1. Biopharmaceutic characteristics of a new extended-release theophylline formulation (Uni-Dur).
Oosterhuis B; Brannan MD; Groen H; Peeters PA; Hempenius J; Radwanski E; Nomeir AA; Affrime MB; Jonkman JH
Ann Allergy Asthma Immunol; 1995 Aug; 75(2):157-61. PubMed ID: 7648380
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic comparison of a once-daily and twice-daily theophylline delivery system.
González MA; Kisicki J; Straughn AB
Clin Ther; 1994; 16(4):686-92. PubMed ID: 7982257
[TBL] [Abstract][Full Text] [Related]
3. Effect of meals and dosage-form modification on theophylline bioavailability from a 24-hour sustained-release delivery system.
González MA; Straughan AB
Clin Ther; 1994; 16(5):804-14. PubMed ID: 7859239
[TBL] [Abstract][Full Text] [Related]
4. NTP Toxicology and Carcinogenesis Studies of Theophylline (CAS No. 58-55-9) in F344/N Rats and B6C3F1 Mice (Feed and Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1998 Aug; 473():1-326. PubMed ID: 12571677
[TBL] [Abstract][Full Text] [Related]
5. Steady-state pharmacokinetics of a once-daily theophylline formulation (Euphylong) when given twice daily.
Götz J; Sauter R; Steinijans VW; Jonkman JH
Int J Clin Pharmacol Ther; 1994 Apr; 32(4):168-73. PubMed ID: 8032575
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic profile of a new sustained-release theophylline pellet formulation for once-daily evening administration.
Steinijans VW; Sauter R; Böhm A; Staudinger H
Arzneimittelforschung; 1988 Aug; 38(8A):1241-50. PubMed ID: 3190813
[TBL] [Abstract][Full Text] [Related]
7. Comparative steady-state bioavailability of sustained-release theophylline preparations: Theo-Dur, Uni-Dur and Xanthium.
Rojanasthien N; Kovjiriyapan K; Manorot M; Pothirat C
Asian Pac J Allergy Immunol; 2001 Jun; 19(2):69-78. PubMed ID: 11699723
[TBL] [Abstract][Full Text] [Related]
8. Comparative steady-state bioavailability of Theo-24 and Theo-Dur in healthy men.
Dockhorn RJ; Cefali EA; Straughn AB
Ann Allergy; 1994 Mar; 72(3):218-22. PubMed ID: 8129214
[TBL] [Abstract][Full Text] [Related]
9. Theophylline levels after single daily and divided dosing of a once-a-day theophylline preparation in asthmatic children.
Boner AL; Sette L; Vallone G; Plebani M; Messori A
Ann Allergy; 1989 Feb; 62(2):149-53. PubMed ID: 2919803
[TBL] [Abstract][Full Text] [Related]
10. Bioequivalence of a new sustained-release formulation of sodium valproate, valproate modified-release granules, compared with existing sustained-release formulations after once- or twice-daily administration.
Dulac O; Alvarez JC
Pharmacotherapy; 2005 Jan; 25(1):35-41. PubMed ID: 15767218
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study].
Trinquand C; Romanet JP; Nordmann JP; Allaire C;
J Fr Ophtalmol; 2003 Feb; 26(2):131-6. PubMed ID: 12660585
[TBL] [Abstract][Full Text] [Related]
12. Serum theophylline profile with once-daily theophylline (Uniphyl) following conversion from intravenous theophylline in adult asthmatic patients.
Fradette M; Babich M; Friesen EG; Archibald JS; Babul N
Clin Ther; 1994; 16(2):160-8. PubMed ID: 8062311
[TBL] [Abstract][Full Text] [Related]
13. Bioavailability of a slow-release theophylline capsule given twice daily to preschool children with chronic asthma: comparison with liquid theophylline.
Sallent J; Hill M; Stecenko A; McKenzie M; Hendeles L
Pediatrics; 1988 Jan; 81(1):116-20. PubMed ID: 3336577
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
[TBL] [Abstract][Full Text] [Related]
15. A novel slow-release formulation of lithium carbonate (Carbolithium Once-A-Day) vs. standard Carbolithium: a comparative pharmacokinetic study.
Castrogiovanni P
Clin Ter; 2002; 153(2):107-15. PubMed ID: 12078335
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacokinetics of a theophylline sustained-release formulation after single and twice daily dosage].
Fuchs WS; von Nieciecki A; Pabst G; Müller M; Dilger C; Gay S; Laicher A; Stanislaus F
Arzneimittelforschung; 1998 May; 48(5A):589-92. PubMed ID: 9676350
[TBL] [Abstract][Full Text] [Related]
17. An open study of tolerability and pharmacokinetics of raclopride extended release capsules in psychiatric patients: a Canadian study.
Gendron A; Sirois G; Nair NP; Bloom D; Movin-Osswald G; Uppfeldt G
J Psychiatry Neurosci; 1995 Jul; 20(4):287-96. PubMed ID: 7647082
[TBL] [Abstract][Full Text] [Related]
18. Theophylline absorption from sustained-release products: comparative steady-state bioavailability of once-daily Theo-Dur, Theo-24, and Uniphyl.
Hurwitz A; Karim A; Burns TS
J Clin Pharmacol; 1987 Nov; 27(11):855-61. PubMed ID: 3429692
[TBL] [Abstract][Full Text] [Related]
19. Once-a-day dosing with theophylline: a comparison of four sustained-release products.
Minotti DA; Altman LC; Ayars GH; Popick FR; Benn VJ
Ann Allergy; 1992 Jun; 68(6):500-6. PubMed ID: 1610026
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin.
Gupta SK; Sathyan G
J Clin Pharmacol; 1999 Mar; 39(3):289-96. PubMed ID: 10073329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
